This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Reneo Pharmaceuticals Dividends and Buybacks

Dividend criteria checks 0/6

Reneo Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

6.5%

Buyback Yield

Total Shareholder Yield	6.5%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

Recent updates

We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Oct 03

Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth

Apr 25

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Nov 22

We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Aug 09

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Apr 22

We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth

Jan 20

Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation

Oct 02

Our First Look At Reneo Pharmaceuticals

Aug 15

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if RPHM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RPHM's dividend payments have been increasing.

Dividend Yield vs Market

Reneo Pharmaceuticals Dividend Yield vs Market

How does RPHM dividend yield compare to the market?
Segment	Dividend Yield
Company (RPHM)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.5%
Industry Average (Biotechs)	2.4%
Analyst forecast (RPHM) (up to 3 years)	0%

Notable Dividend: Unable to evaluate RPHM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RPHM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate RPHM's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RPHM has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/10/06 23:17
End of Day Share Price	2024/10/04 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Reneo Pharmaceuticals, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Jason Zemansky	BofA Global Research
Xiaodong Zhang	H.C. Wainwright & Co.

This company is no longer active

Reneo Pharmaceuticals Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM) announces an Equity Buyback for 576,443 shares, for $4.4 million.

Recent updates

Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell Small Cap Comp Value Index

OnKure, Inc. entered into an agreement to acquire Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM)

New major risk - Revenue and earnings growth

Concentra Biosciences, LLC submitted a non-binding proposal to acquire Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM) for $60.8 million.

Price target decreased by 18% to US$20.98

Reneo Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM) announces an Equity Buyback for 576,443 shares, for $4.4 million.

We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Chief Development Officer notifies of intention to sell stock

New minor risk - Profitability

Price target decreased by 9.1% to US$24.40

Reneo Pharmaceuticals, Inc. announced that it has received $5 million in funding from Abingworth LLP

Reneo Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from Abingworth LLP

Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth

Reneo Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target increased to US$26.83

Founder & Executive Chairman exercised options to buy US$165k worth of stock.

We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Reneo Pharmaceuticals, Inc. Appoints Roshawn Blunt to Its Board of Directors

Reneo Pharmaceuticals, Inc. Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study

Reneo Pharmaceuticals, Inc. to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases

Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2500 Value Index

Price target decreased to US$24.60

Price target decreased to US$30.00

High number of new directors

Dr. Lon Cardon Not Stands for Re-Election as Member of the Board of Reneo Pharmaceuticals, Inc

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Reneo Pharmaceuticals, Inc. Announces Senior Leadership Promotions

Vineet R. Jindal to Resign as Reneo Pharmaceuticals, Inc.'s Chief Financial Officer, Effective March 31, 2022

We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth

High number of new directors

Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation

President recently bought US$64k worth of stock

Our First Look At Reneo Pharmaceuticals

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources